SOURCE-LINKED STUDY SUMMARY
Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Abstract summarized · Quality not appraised
- Studied
- This 48-hour cell experiment compared untreated HepG2 liver cells, free-fatty-acid-treated cells, and fatty-acid-treated cells exposed to liraglutide. It measured cellular lipids, oxidative-stress markers, iron, and antioxidant activity.
- Who / model
- The model used HepG2 cells rather than animals or people; the abstract did not state the number of cell replicates.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- Found
- Liraglutide partially reversed fatty-acid-induced changes, reducing malondialdehyde and iron while lowering TFR1 and increasing NRF2 and GPX4 expression.
- Limits
- This was a cell-line mechanism study, so it does not establish clinical liver protection or safety in humans.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Research findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.